Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer
- Conditions
- Stage III Cervical CancerCervical AdenocarcinomaStage IB Cervical CancerStage II Cervical Cancer
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Institut de Cancérologie de Lorraine
- Target Recruit Count
- 48
- Registration Number
- NCT02880007
- Locations
- 🇫🇷
Centre Georges-François Leclerc, Dijon, France
🇫🇷Centre Val d'Aurelle, Montpellier, France
🇫🇷Centre Paul Strauss, Strasbourg, France
Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
- Conditions
- Invasive Ductal Breast CancerTubular Breast CancerMucinous Breast CancerInflammatory Breast Cancer
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 290
- Registration Number
- NCT02879513
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, Shanghai, China
Radiochemotherapy in Elderly Patients With Oesophagus Cancer
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 23
- Registration Number
- NCT02879227
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers
- Conditions
- Gall Bladder Cancers
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 314
- Registration Number
- NCT02867865
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, Maharashtra, India
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 367
- Registration Number
- NCT02864251
- Locations
- 🇺🇸
Local Institution - 0033, Los Angeles, California, United States
🇺🇸Torrance Memorial Physican Network, Redondo Beach, California, United States
🇺🇸Baylor Scott and White Research Institute, Temple, Texas, United States
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 36
- Registration Number
- NCT02862535
EDOCH Alternating With DHAP for New Diagnosed Younger MCL
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Target Recruit Count
- 55
- Registration Number
- NCT02858804
- Locations
- 🇨🇳
Shuhua Yi, Tianjin, China
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
- Conditions
- Stage IIIA Hilar CholangiocarcinomaStage IVA Extrahepatic Bile Duct CancerStage IVA Intrahepatic CholangiocarcinomaNon-Resectable CholangiocarcinomaStage III Intrahepatic CholangiocarcinomaUnresectable Extrahepatic Bile Duct CarcinomaStage III Extrahepatic Bile Duct CancerStage IIIB Hilar CholangiocarcinomaStage IVB Extrahepatic Bile Duct CancerStage IVB Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: CisplatinDrug: Gemcitabine HydrochlorideOther: Laboratory Biomarker AnalysisOther: Pharmacological StudyDrug: Ricolinostat
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02856568
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
- Conditions
- Urothelial Carcinoma Associated 1 RNA, Human
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1010
- Registration Number
- NCT02853305
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2016-07-27
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Ligartis GmbH
- Registration Number
- NCT02845050
- Locations
- 🇩🇪
Dept. Urology, University Hospital Marburg, Marburg/ Lahn, Baldingerstraße, Germany
🇩🇪Dept. Urology, University Hospital Tübingen, Tübingen, Hoppe-Seyler-Straße 3, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.